clinical trial · NCT04697056
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
IchthyosisImsidolimabplacebo
brief summary
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
started
Jan 25, 2021
primary completion
Nov 19, 2021
completion
Nov 19, 2021
last updated
Sep 16, 2025
detailed description
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of imsidolimab compared with placebo in adolescent and adult participants with ichthyosis. This study will also characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in participants with ichthyosis.
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol